ALTG at the American Society for Clinical Oncology Annual Scientific Meeting
ALTG study DREAM, led by Prof Anna Nowak was selected for oral presentation at the ASCO Annual Scientific Meeting on June 1-5 in Chicago. DREAM is evaluating the activity, safety and tolerability of the combination of durvalumab with chemotherapy in patients with mesothelioma. DREAM completed the enrolment phase of 54 patients ahead of schedule. Early results revealed durvalumab as first line treatment with cisplatin and pemetrexed had higher rates of six month progression free survival (PFS6) and overall response rate (ORR) than expected for chemotherapy alone, with acceptable tolerability. The final result of PFS6 for all 54 patients will be reported in late 2018. A phase III clinical trial is currently in discussion. Clinical trial information: ALTG 15/003.